These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25797498)

  • 1. White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.
    Papaluca M; Greco M; Tognana E; Ehmann F; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2015 May; 8(3):353-60. PubMed ID: 25797498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative.
    Laverty H; Gunn M; Goldman M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):545-8. PubMed ID: 23136843
    [No Abstract]   [Full Text] [Related]  

  • 5. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for children and adolescents with cancer: the need for novel development pathways.
    Vassal G; Zwaan CM; Ashley D; Le Deley MC; Hargrave D; Blanc P; Adamson PC
    Lancet Oncol; 2013 Mar; 14(3):e117-24. PubMed ID: 23434337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European Innovative Medicines Initiative: Progress to Date.
    Faure JE; Dyląg T; Norstedt I; Matthiessen L
    Pharmaceut Med; 2018; 32(4):243-249. PubMed ID: 30174434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Innovative Medicines Initiative moves translational immunology forward.
    Goldman M; Wittelsberger A; De Magistris MT
    Eur J Immunol; 2013 Feb; 43(2):298-302. PubMed ID: 23534061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A proposal for reforming psychologists' training in France and in the European Union].
    Bouchard JP
    Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial lessons from public-private partnerships in drug and vaccine development.
    Wheeler C; Berkley S
    Bull World Health Organ; 2001; 79(8):728-34. PubMed ID: 11545329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development for children: how is pharma tackling an unmet need?
    Hawcutt DB; Smyth RL
    IDrugs; 2008 Jul; 11(7):502-7. PubMed ID: 18600597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in public-private partnerships to fight neglected diseases.
    Gustavsen K; Hanson C
    Health Aff (Millwood); 2009; 28(6):1745-9. PubMed ID: 19887415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Government action needed to step up research and development for world's most neglected diseases.
    Pecoul B
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):841-3. PubMed ID: 16307495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.